Literature DB >> 9623690

Alpha1-antitrypsin deficiency alleles and the Taq-I G-->A allele in cystic fibrosis lung disease.

R Mahadeva1, R C Westerbeek, D J Perry, J U Lovegrove, D B Whitehouse, N R Carroll, R I Ross-Russell, A K Webb, D Bilton, D A Lomas.   

Abstract

Cystic fibrosis (CF) is characterized by progressive and ultimately fatal pulmonary disease although there are notable variations in clinical features. This heterogeneity is thought to lie outside the cystic fibrosis transmembrane regulator (CFTR) gene locus and may stem from deficiencies in the antiproteinase screen that protects the lung from proteolytic attack. One hundred and fifty seven patients were recruited from two UK CF centres. The serum concentrations of alpha1-antitrypsin, alpha1-antichymotrypsin and C-reactive protein (CRP) were determined and patients were screened for the common S and Z deficiency alleles of alpha1-antitrypsin and the G-->A mutation in the 3' noncoding region of the alpha1-antitrypsin gene (Taq-I G-->A allele). Alpha1-antitrypsin deficiency phenotypes were detected in 20 (16 MS, 1 S and 3 MZ) out of 147 unrelated tested CF patients and were, surprisingly, associated with significantly better lung function (adjusted mean forced expiratory volume in one second (FEV1) 62.5% of predicted for deficient group and 51.1% pred for normal alleles; p=0.043). The Taq-I G-->A allele was found in 21 out of 150 unrelated patients and had no significant effect on CF lung disease or on levels of alpha1-antitrypsin during the inflammatory response. We show here that, contrary to current thinking, common mutations of alpha1-antitrypsin that are associated with mild to moderate deficiency of the protein predict a subgroup of cystic fibrosis patients with less severe pulmonary disease. Moreover, the Taq-I G-->A allele has no effect on serum levels of alpha1-antitrypsin in the inflammatory response, which suggests that the previously reported association of the Taq-I G-->A allele with chronic obstructive pulmonary disease is not mediated by its effect on the serum level of alpha1-antitrypsin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9623690     DOI: 10.1183/09031936.98.11040873

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  16 in total

Review 1.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

Review 2.  Modifier genes in Mendelian disorders: the example of cystic fibrosis.

Authors:  Garry R Cutting
Journal:  Ann N Y Acad Sci       Date:  2010-12       Impact factor: 5.691

3.  Alpha-1 antitrypsin deficiency alleles and severe cystic fibrosis lung disease.

Authors:  R Mahadeva; S Stewart; D Bilton; D A Lomas
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

4.  Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency.

Authors:  Daniel J Smith; Paul R Ellis; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

Review 5.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

6.  Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis.

Authors:  R Mahadeva; L Sharples; R I Ross-Russell; A K Webb; D Bilton; D A Lomas
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

7.  Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.

Authors:  R Mahadeva; A C Dunn; R C Westerbeek; L Sharples; D B Whitehouse; N R Carroll; R I Ross-Russell; A K Webb; D Bilton; D A Lomas; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

Review 8.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

9.  Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study.

Authors:  R Mahadeva; K Webb; R C Westerbeek; N R Carroll; M E Dodd; D Bilton; D A Lomas
Journal:  BMJ       Date:  1998-06-13

Review 10.  Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction.

Authors:  A J Sandford; E K Silverman
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.